Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) EPS (Basic) (2023 - 2025)

Historic EPS (Basic) for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to -$0.57.

  • CG Oncology's EPS (Basic) fell 9000.0% to -$0.57 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.04, marking a year-over-year increase of 6229.21%. This contributed to the annual value of -$1.41 for FY2024, which is 9099.87% up from last year.
  • Per CG Oncology's latest filing, its EPS (Basic) stood at -$0.57 for Q3 2025, which was down 9000.0% from -$0.54 recorded in Q2 2025.
  • Over the past 5 years, CG Oncology's EPS (Basic) peaked at -$0.28 during Q2 2024, and registered a low of -$4.47 during Q4 2023.
  • Moreover, its 3-year median value for EPS (Basic) was -$0.54 (2025), whereas its average is -$1.69.
  • As far as peak fluctuations go, CG Oncology's EPS (Basic) surged by 9287.53% in 2024, and later tumbled by 9285.71% in 2025.
  • Over the past 3 years, CG Oncology's EPS (Basic) (Quarter) stood at -$4.47 in 2023, then surged by 88.62% to -$0.51 in 2024, then fell by 12.03% to -$0.57 in 2025.
  • Its EPS (Basic) stands at -$0.57 for Q3 2025, versus -$0.54 for Q2 2025 and -$0.45 for Q1 2025.